Project: The development of a novel medicine for advanced prostate cancer
This project will deliver a novel treatment for prostate carcinoma, which is based on a unique and patented compound that is able to reverse Epithelial-Mesenchymal Transition (EMT). EMT is a process associated with cancer invasion, therapy resistance, and the plasticity of cancer- and metastasis-initiating cells. Since EMT is associated with many epithelial cancer types, this drug can be applied to different types of carcinomas including breast, lung, pancreas, skin and bladder cancer.
| Acronym | TREAT-MEMT (Reference Number: 9386) |
| Duration | 01/01/2015 - 01/01/2018 |
| Project Topic | Biological Sciences / Technologies |
| Network | Eurostars 2 |
| Call | Eurostars Cut-Off 2 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 20500 | Oncodrone BV | Coordinator | Netherlands |
| 20501 | Niels Clauson-Kaas A/S | Partner | Denmark |
| 20502 | Pharmacelsus GmbH | Partner | Germany |
| 20503 | Vivo Science GmbH | Partner | Germany |
| 20504 | Radboud University Medical Center | Partner | Netherlands |
| 20505 | Leiden University Medical Center | Partner | Netherlands |
| 20506 | Universität Bern | Partner | Switzerland |